P.1.g.041 RG1662, a new negative allosteric modulator of the gamma-aminobutyric acid Aα5 receptor subtype, does not show convulsions at relevant doses by Wandel, C, Thomas, A, Hernandez, M.C, Ballard-Yardy, T, Knoflach, F, Trube, G, Rothfuss, A, Husar, E, Lennon-Chrimes, S, Bentley, D, d'Ardhuy, X. Liogier, Squassante, L, Noeldeke, J, Khwaja, O

Get full text

P.133 Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431) by Stark, F. Schaedeli, Chavanne, C., Lennon-Chrimes, S., Diack, C., Derks, M., Smith, J.

Get full text

P.210 Safety, tolerability, pharmacokinetics and metabolism of balovaptan, a selective vasopressin 1a receptor antagonist, in healthy subjects by Derks, M., Lennon-Chrimes, S., Guenther, A., Squassante, L., Wandel, C., Paehler, A., Kletzl, H.

Get full text

Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model by Leisegang, Rory, Silber Baumann, Hanna E., Lennon‐Chrimes, Siân, Ito, Hajime, Miya, Kazuhiro, Genin, Jean‐Christophe, Plan, Elodie L.

Get full text

Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man by Hipp, Joerg F., Knoflach, Frederic, Comley, Robert, Ballard, Theresa M., Honer, Michael, Trube, Gerhard, Gasser, Rodolfo, Prinssen, Eric, Wallace, Tanya L., Rothfuss, Andreas, Knust, Henner, Lennon-Chrimes, Sian, Derks, Michael, Bentley, Darren, Squassante, Lisa, Nave, Stephane, Nöldeke, Jana, Wandel, Christoph, Thomas, Andrew W., Hernandez, Maria-Clemencia

Get full text

SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectru... by Bennett, Jeffrey L, Fujihara, Kazuo, Kim, Ho Jin, Marignier, Romain, O'Connor, Kevin C, Sergott, Robert C, Traboulsee, Anthony, Wiendl, Heinz, Wuerfel, Jens, Zamvil, Scott S, Anania, Veronica G, Buffels, Regine, Künzel, Thomas, Lekkerkerker, Annemarie N, Lennon-Chrimes, Siân, Pittock, Sean J

Get full text

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome by Goeldner, Celia, Kishnani, Priya S., Skotko, Brian G., Casero, Julian Lirio, Hipp, Joerg F., Derks, Michael, Hernandez, Maria-Clemencia, Khwaja, Omar, Lennon-Chrimes, Sian, Noeldeke, Jana, Pellicer, Sabine, Squassante, Lisa, Visootsak, Jeannie, Wandel, Christoph, Fontoura, Paulo, d’Ardhuy, Xavier Liogier, De La Torre Fornell, Rafael, Glue, Paul, Hoover-Fong, Julie, Uhlmann, Sonja, Malagón Valdez, Jorge, Marshall, Andrew, Martinón-Torres, Federico, Redondo-Collazo, Lorenzo, Rodriguez-Tenreiro, Carmen, Marquez Chin, Valeria, Michel Reynoso, Adriana G., Mitchell, Ed A., Slykerman, Rebecca F., Wouldes, Trecia, Loveday, Sarah, Moldenhauer, Fernando, Novell, Ramon, Ochoa, Cesar, Rafii, Michael S., Rebillat, Anne-Sophie, Sanlaville, Damien, Sarda, Pierre, Shankar, Rohit, Pulsifer, Margaret, Evans, Casey L., Silva, Alexandra M., McDonough, Mary Ellen, Stanley, Maria, McCary, Lindsay M., Vicari, Stefano, Wilcox, William, Zampino, Giuseppe, Zuddas, Alessandro

Get full text

Safety, Tolerability, and Pharmacokinetics of Intravenous Oseltamivir: Single- and Multiple-Dose Phase I Studies with Healthy Volunteers by BRENNAN, Barbara J, DAVIES, Brian, CIRRINCIONE-DALL, Georgina, MORCOS, Peter N, BERYOZKINA, Anna, CHAPPEY, Colombe, ACEVES BALDO, Pau, LENNON-CHRIMES, Sian, RAYNER, Craig R

Get full text

Effect of oseltamivir treatment on anticoagulation: a cross‐over study in warfarinized patients by Davies, Brian E., Baldó, Pau Aceves, Lennon‐Chrimes, Sian, Brewster, Mike

Get full text

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA A -α5 NAM (basmisanil) on intellectual disability associated with Down syndrome by Goeldner, Celia, Kishnani, Priya S, Skotko, Brian G, Casero, Julian Lirio, Hipp, Joerg F, Derks, Michael, Hernandez, Maria-Clemencia, Khwaja, Omar, Lennon-Chrimes, Sian, Noeldeke, Jana, Pellicer, Sabine, Squassante, Lisa, Visootsak, Jeannie, Wandel, Christoph, Fontoura, Paulo, d'Ardhuy, Xavier Liogier

Get full text

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-[alpha]5 NAM (basmisanil) on intellectual disability associated with Down syndrome by Wouldes, Trecia, Zuddas, Alessandro, Pellicer, Sabine, Redondo-Collazo, Lorenzo, Glue, Paul, Rafii, Michael S, Malagón Valdez, Jorge, Lennon-Chrimes, Sian, d'Ardhuy, Xavier Liogier, De La Torre Fornell, Rafael, Silva, Alexandra M, Mitchell, Ed A, Marshall, Andrew, Stanley, Maria, Hipp, Joerg F, Derks, Michael, Shankar, Rohit, Uhlmann, Sonja, Pulsifer, Margaret, Casero, Julian Lirio, Rebillat, Anne-Sophie, Visootsak, Jeannie, Kishnani, Priya S, Squassante, Lisa, Noeldeke, Jana, Hernandez, Maria-Clemencia, Fontoura, Paulo, Sanlaville, Damien, Zampino, Giuseppe, Goeldner, Celia, Loveday, Sarah, McDonough, Mary Ellen, Khwaja, Omar, Wandel, Christoph, Wilcox, William, Slykerman, Rebecca F, Ochoa, Cesar, Martinón-Torres, Federico, Marquez Chin, Valeria, Evans, Casey L, Michel Reynoso, Adriana G, McCary, Lindsay M, Vicari, Stefano, Skotko, Brian G, Hoover-Fong, Julie, Moldenhauer, Fernando, Sarda, Pierre, Novell, Ramon, Rodriguez-Tenreiro, Carmen

Get full text

Basmisanil, a highly selective GABA A -α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man by Hipp, Joerg F, Knoflach, Frederic, Comley, Robert, Ballard, Theresa M, Honer, Michael, Trube, Gerhard, Gasser, Rodolfo, Prinssen, Eric, Wallace, Tanya L, Rothfuss, Andreas, Knust, Henner, Lennon-Chrimes, Sian, Derks, Michael, Bentley, Darren, Squassante, Lisa, Nave, Stephane, Nöldeke, Jana, Wandel, Christoph, Thomas, Andrew W, Hernandez, Maria-Clemencia

Get full text